Business Context and Reporting Period
This Form 8-K filing by Liminatus Pharma, Inc. (LIMN) covers events occurring between June 29, 2026, and July 2, 2026. The Company, an emerging growth company, announced and subsequently consummated a merger with InnocsAI LLC. The transaction was structured to allow closing prior to obtaining stockholder approval by utilizing a combination of common stock and newly designated non-voting convertible preferred stock.
Key Financial Metrics and Transaction Details
The filing does not provide standard financial metrics such as revenue, profit, cash flow, margins, or debt levels. The primary financial activity reported is the issuance of equity securities in connection with the acquisition of InnocsAI.
- Common Stock Issued: 11,188,729 shares issued to former InnocsAI members.
- Preferred Stock Issued: 158,881.1271 shares of Series A Non-Voting Convertible Preferred Stock.
- Preferred Stock Conversion: Each share converts into 10,000 shares of common stock, subject to stockholder approval.
- Authorized Preferred Stock: 160,000 shares of Series A Preferred Stock authorized.
- Valuation Context: The merger consideration was structured to issue up to 19.99% of outstanding common stock immediately without stockholder approval, with the balance in convertible preferred stock.
Material Changes Versus Prior Period
The filing details a material change in corporate structure and capitalization rather than operational performance changes:
- Acquisition: InnocsAI merged into a wholly-owned subsidiary of Liminatus Pharma, with Liminatus Pharma continuing as the surviving entity.
- Capital Structure: The Company amended its certificate of incorporation to designate Series A Non-Voting Convertible Preferred Stock, which ranks on parity with common stock regarding dividends and liquidation but carries no voting rights.
- Agreements: Entered into an Amended and Restated Merger Agreement, a Registration Rights Agreement (providing piggy-back and Form S-3 rights), and a Non-Competition and Non-Solicitation Agreement with key InnocsAI employees.
Guidance, Outlook, Risks, and Contingencies
Outlook and Management Commentary: The Company intends to hold a stockholder meeting to approve the issuance of common stock issuable upon conversion of the Series A Preferred Stock. A preliminary proxy statement is expected to be filed with the SEC.
Risks and Contingencies:
- Stockholder Approval: Conversion of Series A Preferred Stock into common stock is contingent upon stockholder approval required by Nasdaq listing rules.
- Liquidity and Going Concern: The filing explicitly notes the risk of the Company's need for additional capital to fund planned programs and to continue as a going concern.
- Listing Compliance: Risks related to maintaining compliance with Nasdaq continued listing requirements to prevent delisting.
- Transaction Risks: Risks include failure to realize anticipated benefits, delays in consummating transactions, and the impact of global economic conditions or pandemics.
Important Facts for Investor Verification
- Verify the exact number of outstanding shares prior to the merger to calculate the precise dilution impact of the 11,188,729 common shares and the potential 1,588,811,271 shares underlying the Series A Preferred Stock.
- Confirm the timeline and outcome of the upcoming stockholder vote required to enable the conversion of Series A Preferred Stock.
- Review the upcoming proxy statement for details on the valuation of InnocsAI and the specific terms of the non-compete agreements.
- Assess the Company's current cash position and capital raise plans, given the explicit disclosure regarding the need for additional capital to operate as a going concern.
- Monitor Nasdaq compliance status, as the transaction structure was specifically designed to navigate listing rules regarding share issuance limits.